 |
Oprelvekin |
|---|---|
| Trade Name | Neumega |
| Orphan Indication | Prevention of severe chemotherapy-induced thrombocytopenia |
| USA Market Approval | USA |
| USA Designation Date | 1996-12-17 00:00:00 |
| Sponsor | Genetics Institute, Inc.;87 Cambridge Park Drive;Cambridge, Massachusetts, 02140 |
